Estrella Immunopharma, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 15, 2024 and accepted by EDGAR at May 14, 2024, 21:49 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-01-01 to 2024-03-31 | $25.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-07-01 to 2024-03-31 | $583.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$469.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-07-01 to 2024-03-31 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$469.5k | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-07-01 to 2024-03-31 | −$3.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-07-01 to 2024-03-31 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-07-01 to 2024-03-31 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 35,594,082 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-07-01 to 2024-03-31 | 24,038,405 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-07-01 to 2024-03-31 | −$15.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-03-31 | $4.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $8.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $8.6m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $138.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $138.5k | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-03-31 | $8.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-043126. Last ingested by Listed: Nov 4, 2026, 07:37 ET. Listed shows no prices and gives no investment advice.